Beacon Biosignals is building the future of brain health with AI-driven neurotechnology. They are focused on bringing precision neuroscience to clinical trials and accelerating drug development for neurological and psychiatric conditions that currently lack effective treatments.

Their AI-powered platform uses EEG technology to measure brain activity during sleep, providing stable and consistent data to identify biomarkers, assess treatment effects, and stratify patients. This technology helps clinical development teams better understand and treat major depressive disorder, schizophrenia, bipolar disorder, and other neurological diseases.

Beacon offers an end-to-end solution for EEG biomarkers in clinical research, including an FDA-cleared headband for high-fidelity sleep EEG capture, AI-driven analytics software for monitoring and assessment, and full-service clinical trial support.

The company’s biomarkers transform drug development by identifying dose-dependent drug effects, characterizing patient populations, expanding labeling language, and allowing early tracking of disease progression. Their platform supports therapeutic development from discovery to clinical practice, optimizing trials and providing real-world evidence.